|
|
||||||||
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Articles in PresS, published online ahead of print October 31, 2001
Am J Physiol Cell Physiol, 10.1152/ajpcell.00343.2001
Submitted on July 25, 2001
Accepted on October 24, 2001
1 Diabetes and Metabolism Unit, Boston University School of Medicine, Boston, MA, USA
2 Pfizer Central Research, Pfizer Inc., Groton, CT, USA
3 Whitaker Cardiovascular Institute, Boston University School of Medicine, Boston, MA, USA
* To whom correspondence should be addressed. E-mail: jkeaney{at}bu.edu.
Nitric oxide (NO) plays an important role in the control of numerous vascular functions including basal Na+-K+-adenosine triphosphatase (Na+-K+-ATPase) activity in arterial tissue. Hyperglycemia inhibits Na+-K+-ATPase activity in rabbit aorta, in part, through diminished bioactivity of NO. The precise mechanism(s) for such observations, however, are not yet clear. The purpose of this study was to examine the role of superoxide in modulating NO-mediated control of Na+-K+-ATPasein response to hyperglycemia. Rabbit aorta incubated with hyperglycemic glucose concentrations (44 mM) demonstrated a 50% reduction in Na+-K+-ATPase activity that was abrogated by superoxide dismutase (SOD). Hyperglycemia also produced a 50% increase in steady-state vascular superoxide measured by lucigenin-enhanced chemiluminescence that was closely associated with reduced Na+-K+-ATPase activity. Specifically, the hyperglycemia-induced increase in vascular superoxide was endothelium-dependent, inhibited by L-arginine, and stimulated by N
-nitro-L-arginine. Aldose reductase inhibition with zopolrestat also inhibited the hyperglycemia-induced increase in vascular superoxide. In each manipulation of vascular superoxide, a reciprocal change in Na+-K+-ATPase activity was observed. Finally, a commercially available preparation of Na+-K+-ATPase was inhibited by pyrogallol, a superoxide generator. These data suggest that hyperglycemia induces an increase in endothelial superoxide that inhibits the stimulatory effect of NO on vascular Na+-K+-ATPase activity.
This article has been cited by other articles:
![]() |
R. Ananthakrishnan, M. Kaneko, Y. C. Hwang, N. Quadri, T. Gomez, Q. Li, C. Caspersen, and R. Ramasamy Aldose reductase mediates myocardial ischemia-reperfusion injury in part by opening mitochondrial permeability transition pore Am J Physiol Heart Circ Physiol, February 1, 2009; 296(2): H333 - H341. [Abstract] [Full Text] [PDF] |
||||
![]() |
E. Toth, A. Racz, J. Toth, P. M. Kaminski, M. S. Wolin, Z. Bagi, and A. Koller Contribution of polyol pathway to arteriolar dysfunction in hyperglycemia. Role of oxidative stress, reduced NO, and enhanced PGH2/TXA2 mediation Am J Physiol Heart Circ Physiol, November 1, 2007; 293(5): H3096 - H3104. [Abstract] [Full Text] [PDF] |
||||
![]() |
W. Sun, P. J. Oates, J. B. Coutcher, C. Gerhardinger, and M. Lorenzi A selective aldose reductase inhibitor of a new structural class prevents or reverses early retinal abnormalities in experimental diabetic retinopathy. Diabetes, October 1, 2006; 55(10): 2757 - 2762. [Abstract] [Full Text] [PDF] |
||||
![]() |
I. G. Obrosova, P. Pacher, C. Szabo, Z. Zsengeller, H. Hirooka, M. J. Stevens, and M. A. Yorek Aldose Reductase Inhibition Counteracts Oxidative-Nitrosative Stress and Poly(ADP-Ribose) Polymerase Activation in Tissue Sites for Diabetes Complications Diabetes, January 1, 2005; 54(1): 234 - 242. [Abstract] [Full Text] [PDF] |
||||
![]() |
Z. Dagher, Y. S. Park, V. Asnaghi, T. Hoehn, C. Gerhardinger, and M. Lorenzi Studies of Rat and Human Retinas Predict a Role for the Polyol Pathway in Human Diabetic Retinopathy Diabetes, September 1, 2004; 53(9): 2404 - 2411. [Abstract] [Full Text] [PDF] |
||||
![]() |
B.-L. Johansson, J. Wahren, and J. Pernow C-peptide increases forearm blood flow in patients with type 1 diabetes via a nitric oxide-dependent mechanism Am J Physiol Endocrinol Metab, October 1, 2003; 285(4): E864 - E870. [Abstract] [Full Text] [PDF] |
||||
![]() |
I. G. Obrosova, A. G. Minchenko, R. Vasupuram, L. White, O. I. Abatan, A. K. Kumagai, R. N. Frank, and M. J. Stevens Aldose Reductase Inhibitor Fidarestat Prevents Retinal Oxidative Stress and Vascular Endothelial Growth Factor Overexpression in Streptozotocin-Diabetic Rats Diabetes, March 1, 2003; 52(3): 864 - 871. [Abstract] [Full Text] [PDF] |
||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH |
| Visit Other APS Journals Online |